Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop

Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare progressive genetic disease effecting one in a million individuals. During their life, patients with FOP progressively develop bone in the soft tissues resulting in increasing immobility and early death. A mutation in the ACVR1 gene was id...

Full description

Bibliographic Details
Main Authors: Ruben D. de Ruiter, Bernard J. Smilde, Gerard Pals, Nathalie Bravenboer, Petra Knaus, Ton Schoenmaker, Esmée Botman, Gonzalo Sánchez-Duffhues, Maurizio Pacifici, Robert J. Pignolo, Eileen M. Shore, Marjolein van Egmond, Hans Van Oosterwyck, Frederick S. Kaplan, Edward C. Hsiao, Paul B. Yu, Renata Bocciardi, Carmen Laura De Cunto, Patricia Longo Ribeiro Delai, Teun J. de Vries, Susanne Hilderbrandt, Richard T. Jaspers, Richard Keen, Peter Koolwijk, Rolf Morhart, Jan C. Netelenbos, Thomas Rustemeyer, Christiaan Scott, Clemens Stockklausner, Peter ten Dijke, James Triffit, Francesc Ventura, Roberto Ravazzolo, Dimitra Micha, Elisabeth M. W. Eekhoff
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Endocrinology
Subjects:
fibrodysplasia ossificans progessiva (FOP)
trials
therapy
disease models
inflammation
angiogenesis
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.732728/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.732728/full

Similar Items